Clinical Trial Update: Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and pharmacokinetics of new oral hPTH(1-34) tablet formulations, compared with EBP05 tablets and subcutaneous Forteo; the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism
• Osteoporosis

Drugs mentioned

• EBP05 (hPTH(1-34) oral tablet)
• Forteo (teriparatide)
• Oral hPTH(1-34) Tablet (experimental formulation) (human parathyroid hormone (1-34))

Snippet

Sponsor: Entera Bio Ltd. | Conditions: Hypoparathyroidism, Osteoporosis | Phase 1 | Status: COMPLETED